Loperamide
| Loperamide | |
|---|---|
| Salts [] | |
|---|---|
| Loperamide hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 477.00 g/mol [1] |
| Melting point | 220-228 [1] |
| Predicted LogP | 5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C29H33ClN2O2 |
| IUPAC name | 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide |
| SMILES | CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4 |
| InChI | InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3 |
| InChIKey | RDOIQAHITMMDAJ-UHFFFAOYSA-N |
| CAS number | 53179-11-6 |
| UNII | 6X9OC3H4II |
| PubChem CID | 3955 |
| Pharmacokinetics[] | |
|---|---|
| Onset | ~1 hour |
| Elimination half-life | 9–14 hours |
| Duration of action | Up–3 days |
| Metabolism | Liver (extensive) |
| Excretion | Feces (30–40%), urine (1%) |
| Routes of administration | By mouth |
| Toxicity [] | |
|---|---|
| LD50 | Dog: - iv: 2.8 mg/kg Guinea: - pig oral: 41.5 mg/kg [1] |
Loperamide (also known as Loperamida, Loperamidum, Fortasec, 258-416-5, Ioperamide, Maalox Anti-Diarrheal, Loperacap, A1cmv, Apo-Loperamide or Nu-Loperamide) is a opioid substance of the phenylpropylamine class.
Chemistry
Salts []
Stereochemistry []
Loperamide is achiral.
Druglikeness
Lipinski's rule of five
Loperamide matches Lipinski's rule of five.Reagents
There are currently 3 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | no color change | |
| Mandelin | no color change |
Pharmacology
ATC Classification
- alimentary tract and metabolism (A)
- antidiarrheals, intestinal antiinflammatory/antiinfective agents (A07)
- antipropulsives (A07D)
- antipropulsives (A07DA)
- (A07DA03)
- loperamide (A07DA03)
MeSH Classification
- antidiarrheals (M0001388)
Mechanism of action []
Enteric neurons synthesize and release endogenous opioid peptides and other neurotransmitters, such as acetylcholine and substance P. Endogenous opioids bind to opioid receptors expressed on these neurons to regulate gastrointestinal signalling, motility, and balance of fluids and electrolytes. Loperamide acts on the mu (μ)-opioid receptor expressed on the circular and longitudinal intestinal muscle. Receptor binding leads to the recruitment of G-protein receptor kinases and the activation of downstream molecular cascades that inhibit enteric nerve activity. By inhibiting the excitability of enteric neurons, loperamide suppresses neurotransmitter release, pre-synaptic and post-synaptic inhibition of transmission of excitatory and inhibitory motor pathways, and secretomotor pathways. Loperamide inhibits the release of acetylcholine and prostaglandins, thereby reducing propulsive peristalsis and increasing intestinal transit time. Loperamide stimulates the intestinal absorption of water and electrolytes by inhibiting calmodulin. Loperamide can bind to and hyperpolarize submucosal secretomotor neurons, promoting dry, hard stools. [1]
Interactions []
Medical side effects []
46 side effects listed on drug labels in SIDER 4.1 (loperamide).
- Constipation
- Abdominal pain
- Abdominal colic
- Nausea
- Abdominal distension
- Distention
- Abdominal bloating
- Gastrointestinal pain
- Anaphylactic shock
- Anaphylactoid reaction
- Angioedema
- Dizziness
- Somnolence
- Dyspepsia
- Toxic epidermal necrolysis
- Erythema multiforme
- Stevens-Johnson syndrome
- Dermatitis
- Rash
- Asthenia
- Fatigue
- Flatulence
- Gastrointestinal disorder
- Hypersensitivity
- Immune system disorder
- Megacolon
- Megacolon toxic
- Nervous system disorder
- Ileus paralytic
- Pruritus
- Loss of consciousness
- Urethral disorder
- Urinary tract disorder
- Urticaria
- Vomiting
- Dry mouth
- Urinary retention
- Skin disorder
- Discomfort
- Dermatitis bullous
- Altered state of consciousness
- Depressed level of consciousness
- Ileus
- Headache
- Abdominal pain upper
- Diarrhoea
Indications
- Chronic diarrhea
- Diarrhoea
- Hepatic impairment
- Inflammatory bowel disease
- Renal impairment
Subjective effects []
Experience reports
Erowid
There are currently 19 experience reports involving loperamide on Erowid: []- "Surviving a Week With Almost No Withdrawals" by Floyd
- "Dangerous OTC Lame Drug" by Nekro
- "Bridging the Gaps with an Antidiarrheal" by ErichZann
- "WHAT!? a Good Mood in Withdrawals?" by DebbyDrugs524
- "Feelings of Wellbeing, Slight Euphoria" by majtom
- "Incredibly Itchy and Zero Euphoria" by Inevitable014
- "Almost All of My Symptoms Have Abated" by Vic
- "How I Quit Heroin With Mild Withdrawals" by Ford
- "The Forgotten Opioid" by The Monkey Mantra
- "Just Okay" by Dee
- "Recipe for Withdrawals" by Sleepdust
- "If I Had Only Known" by Nicole F
- "It's True" by Nikki
- "Actually Helps Tremendously" by bran man
- "Wouldn't Say That This Is Anything Amazing" by Herr_Doktor421
- "Mild Effect Smoked" by bran man
- "My New Favorite OTC High" by 409
- "The Sudafed of Opiates" by Cryss Curry
- "Opiate Withdrawal Godsend OTC" by C
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3955, Loperamide. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3955
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Loperamide. UNII: 6X9OC3H4II. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6X9OC3H4II
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Imodium A-D- loperamide hydrochloride solution. DailyMed. 23 September 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76a976d5-8bee-4158-a94d-7fbfc5544fd4
Loperamide Hydrochloride capsule. DailyMed. 30 September 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 05:52:28 |
| drugspro | ok | 2026-11-20 05:52:24 |
| erowid | ok | 2026-11-20 05:52:30 |
| gsrs | ok | 2026-11-20 05:52:25 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0004999) | 2026-11-20 05:52:24 |
| kegg | ok | 2026-11-20 05:52:26 |
| pubchem | ok | 2026-11-20 05:52:24 |
| ok | 2026-11-20 05:52:24 | |
| sider | ok | 2026-11-20 05:52:24 |
| structure | ok | 2026-11-20 05:52:24 |
| wikipedia | ok | 2026-11-20 05:52:24 |